Please see annexed enclosure.
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Laurus Labs delivered strong Q4 FY26 results with total income of INR6,813 crores (23% YoY growth) and EBITDA margin expansion to 26.8% from 20.1% last year. CDMO business reached INR2,080 crores (small molecule CDMO at INR1,896 crores with 38% growth), while Affordable Medicines (Generics) posted INR4,733 crores with 18% growth. Management guided for INR3,000 crores capex over next 2 years to fund capacity expansions including Unit 7 greenfield (production by March 2027), peptide manufacturing (Q2 FY27), fermentation facility (end-2026), and KRKA joint venture formulations. The company aims for CDMO to reach 50% of total sales by FY30, up from current 30%+. Management expressed confidence in maintaining or improving EBITDA margins in FY27, with operating leverage expected to kick in as new capacities come online.
The company is executing well on its transformation strategy with improving margins and clear capacity expansion plans. Shareholders can expect continued margin improvement and growth driven by CDMO and new product launches, though heavy capex spend (INR3,000 crores in 2 years) will keep debt elevated.